Having trouble accessing articles? Reset your cache.

Microplasmin meets Phase III endpoint

ThromboGenics N.V. (Euronext:THR) said a single intravitreal injection of microplasmin met the primary

Read the full 137 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE